{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-23-000145","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.153169+00:00","generated_at":"2026-06-08T16:24:28.728669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Denali reports Q3 net loss $99.4M; cuts 2023 expense growth outlook to 15-20%","bullets":["Net loss $99.4M (vs $103.3M); revenue $1.3M (vs $3.6M). Cash $1.12B.","FY2023 cash op expense growth guidance reduced to 15-20% from prior 25-30%.","Sanofi's eclitasertib failed CLE Phase 2; UC study continues. Biogen amended LRRK2 deal.","Pipeline: DNL310 Phase 2/3 enrolling; DNL126 Phase 1/2 starting; OTV advancing 2 candidates to clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-23-000145","json":"https://secwatch.observer/filing/0001714899-23-000145.json","markdown":"https://secwatch.observer/filing/0001714899-23-000145.md","text":"https://secwatch.observer/filing/0001714899-23-000145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/0001714899-23-000145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/dnli-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:24:28.728669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c92931a0b16730ae5249894292066c30550325cb","claim":"Denali Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Denali Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/0001714899-23-000145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}